FUNCTIONAL STATUS OF VASCULAR ENDOTHELIUM IN DIABETES MELLITUS
AbstractNormal endothelial cells synthesize and release biologically active substances. These substances maintain homeostasis through adequate blood flow, delivery of nutrients, activation and inhibition of coagulation proteins, prevention of thrombosis and diapedesis of leukocyte. Endothelial dysfunction implies failure of vascular endothelium to perform its normal functions of vasodilatation and vasoconstriction. It results from an imbalance between endothelium derived constricting and relaxing factors. Altered endothelial cell activity predisposes to increased production of vasoconstrictors, i.e., prostaglandins, endothelins, glycated proteins, endothelial adhesion molecules and platelet and vascular growth factors. These changes enhance vasomotor tone, vascular permeability, growth and remodeling of the vessels. Diabetes is associated with abnormalities of vascular endothelium. Several regulatory vasodilators and vasoconstrictors are altered in diabetes leading to diabetic vascular complications. Balance between dilating and constricting substances is altered and is shifted towards vasoconstriction in diabetes. Disturbances in the endothelial functions lead to increased platelet adhesion and aggregation in patients with diabetes. Activated platelets interact with endothelial cells and leukocytes in the genesis of atherosclerosis. High level of Von Willebrand factor(vWF) is a consistent finding in diabetes. Increased vWF level is one of the major risk factors for the development of micro vascular complications. High levels of vWF may predict cardiovascular disease progression in diabetes mellitus.Keywords: Vascular, endothelium, diabetes mellitus
Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 2001;12:383–9.
Rahman S, Rahman T, Ismail AA, Rashid AR. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab 2007;9:767–80.
Paston L, Talor PD. Glaxo/MRS Young Investigator Prize. Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin Sci (Lond) 1995;88:245–55.
Carter AM, Grant P. Vascular homeostasis, adhesion molecules and macrovascular disease in non-insulin dependent diabetes mellitus. Diabet Med 1997;14:423–32.
Galajda P, Martinka E, Mokan M, Kubisz P. Endothelial markers in diabetes mellitus.. Thromb Res 1997;85:63–5.
Martina V, Bruno GA, Trucco F, Zumpano E, Tagliabue M, Di Bisceglie C, et al. Platelet cNOS activity is reduced in patients with IDDM and NIDDM. Thromb Haemost 1998;79:520–2.
Moncada S, Higgs A. The L-arginine–nitric oxide pathway. N Engl J Med 1993;329:2002–12.
Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 2006;5:4. doi:10.1186/1475-2840-5-4
Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651–5.
Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 1996;78:225–30.
Queen LR, Ji Y, Goubareva I, Ferro A. Nitric oxide generation mediated by beta-adrenoceptors is impaired in platelets from patients with type 2 diabetes mellitus. Diabetologia 2003;46:1474–82.
Bohlen HG, Lash JM. Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles. Am J Physiol 1993;265(1 Pt 2):H219–25.
Pieper GM, Meier DA, Hager SR. Endothelial dysfunction in a model of hyperglycemia and hyperinsulinemia. Am J Physiol 1995;269(3 Pt 2):H845–50.
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology and management. JAMA 2002;287:2570–81.
Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite. Biochem Biophys Res Commun 1999;63:681–4.
Zou M, Yesilkaya A, Ullrich V. Peroxynitrite inactivates prostacyclin synthase by heme-thiolatecatalyzed tyrosine nitration. Drug Metab Rev 1999;31:343–9.
El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 2003;162:1995–2004.
Hammes HP, Lin J, Bretzel RG, BrownleeM, Breier G. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998;47:401–6.
Golovchenko I, Goalstone ML, Watson P, Brownlee M, Draznin B. Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappa B induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ Res 2000;87:746–52.
Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004;24:816–23.
Nugent AG, McGurk C, Hayes JR, Johnston GD. Impaired vasoconstriction to endothelin 1 in patients with NIDDM. Diabetes. 1996;45:105-7.
Feener EP, King GL. Vascular dysfunction in diabetes mellitus. Lancet 1997; 350(Suppl 1):SI9–3.
Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859–66.
Inaba T, Ishibashi S, Gotoda T, Kawamura M, Morino N, Nojima Y, et al. Enhanced expression of platelet-derived growth factor-beta receptor by high glucose. Involvement of platelet-derived growth factor in diabetic angiopathy. Diabetes 1996;45:507–12.
Blankenberg FG1, Wen P, Dai M, Zhu D, Panchal SN, Tait JF, et al. Detection of early atherosclerosis with radiolabeled monocyte chemoattractant protein 1 in prediabetic Zucker rats. Pediatr Radiol 2001;31:827–35.
Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 2003;108:1527–32.
Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C. et al. Inhibition of GAPDH activity by poly (ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003;112:1049–57.
Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 1995;76:980–6.
Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001;107:255–64.
Libby P. Changing concepts of atherogenesis. J Intern Med 2000;247:349–58.
Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest 1998;101:1905–15.
Shah P, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins. An idea whose time for testing is coming. Part I. Circulation 2001;104:2376–83.
Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 1994;121:936–41.
Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, et al. Elevated levels of oxidated low density lipoprotein show a positive relationship with the severity of acute coronary syndrome. Circulation 2001;103:1955–60.
Landmesser U, Harrison DG. Oxidant stress and marker for cardiovascular events. Ox marks the spots. Circulation 2001;104:2638–40.
Lyons TJ. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 1993;71:26B–31B.
McMillen DE. Development of vascular complications in diabetes. Vasc Med 1997;2:132–42.
Mazzanti L, Mutus B. Diabetes-induced alterations in platelet metabolism. Clin Biochem 1997;30:509–15.
Rosenblum WI. Platelet adhesion and aggregation without endothelial denudation or exposure of basal lamina and:or collagen. J Vasc Res 1997;34:409–17.
Tschoepe D, Roesen P, Schwippert B, Gries FA. Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis. Semin Thromb Hemost 1993;19:122–8.
Blann AD, Lip GY. Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 diabetes mellitus. Diabet Med 1998;15:634–42.
Maugeri N, Evangelista V, Celardo A, Dell’Elba G, Martelli N, Piccardoni P et al., Polymorphonuclear leukocyte-platelet interaction: role of P-selectin in thromboxane B2 and leukotriens C4 cooperative synthesis. Thromb Haemost 1994;72:450–6.
Ryysy L, Yki-Jarvinen H. Improvement of glycemic control by 1 year of insulin therapy leads to a sustained decrease in sE-selectin concentrations in type 2 diabetes. Diabetes Care 2001;24:549–54.
Yngen M, Ostenson CG, Hu H, Li N, Hjemdahl P, Wallen NH. Enhanced P-selectin expression and increased soluble CD40 ligand in patients with type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Diabetologia 2004;47:537–40.
Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004;291:1978–86.
Tschoepe D, Roesen P, Kaufmann L, Schauseil S, Kehrel B, Ostermann H, et al. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 1990;20:166–70.
Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635–41.
Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998;47:1643–9.
Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000;101:676–81.
Mather K, Laakso M, Edelman S, Hook G, Baron A. Evidence for physiological coupling of insulin-mediated glucose metabolism and limb blood flow. Am J Physiol Endocrinol Metab 2000;279:E1264–70.
Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 2002;277:1794–9.
Liang CP, Han S, Okamoto H, Carnemolla R, Tabas I, Accili D, et al. Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest 2004;113:764–73.
Death AK, Fisher EJ, McGrath KC, Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003;168:263–9.
Derosa G, Avanzini MA, Geroldi D, Fogari R, Lorini R, De Silvestri A, et al. Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes. Diabetes Care 2004;27:273–4.
Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000;108(Suppl 6a):9S–14S.
Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000;49:1939–45.
Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001;135:447–59.
de Man FH, Weverling-Rijnsburger AW, van der Laarse A, Smelt AH, Jukema JW, Blauw GJ. Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvastatin. Arterioscler Thromb Vasc Biol 2000;20:744–50